NASDAQ · KYMR
Healthcare · Biotechnology
$113.15
Down-$1.48 (-1.29%)
Updated Sep 16, 2026, 9:24 AM
SID Score
5.9/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
KYMR closed at $113.15 after 20 trading sessions, down 6.78% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $114.50 | $114.50 | $110.29 | $113.15 | 900.98K |
| Sep 14, 2026 | $116.01 | $117.85 | $114.32 | $114.63 | 499.01K |
| Sep 11, 2026 | $118.40 | $119.93 | $113.74 | $114.96 | 574.19K |
| Sep 10, 2026 | $116.05 | $119.63 | $114.35 | $117.00 | 734.3K |
| Sep 9, 2026 | $115.34 | $120.665 | $113.1778 | $115.43 | 767.42K |
| Sep 8, 2026 | $114.41 | $120.22 | $113.97 | $116.47 | 631.82K |
| Sep 4, 2026 | $115.09 | $118.28 | $112.77 | $117.39 | 378.57K |
| Sep 3, 2026 | $118.63 | $119.26 | $115.55 | $117.28 | 591.62K |
| Sep 2, 2026 | $119.58 | $123.54 | $117.415 | $118.63 | 982.97K |
| Sep 1, 2026 | $116.92 | $119.785 | $116.28 | $119.05 | 576.63K |
| Aug 31, 2026 | $118.60 | $119.93 | $115.97 | $118.81 | 656.83K |
| Aug 28, 2026 | $119.40 | $121.975 | $117.48 | $118.15 | 415.95K |
| Aug 27, 2026 | $124.99 | $125.065 | $119.98 | $120.23 | 595.7K |
| Aug 26, 2026 | $126.24 | $126.315 | $123.39 | $125.55 | 558.34K |
| Aug 25, 2026 | $122.64 | $127.85 | $121.60 | $126.64 | 925.75K |
| Aug 24, 2026 | $119.98 | $121.56 | $116.46 | $121.05 | 466.86K |
| Aug 21, 2026 | $122.87 | $125.71 | $119.77 | $119.80 | 503.43K |
| Aug 20, 2026 | $124.95 | $125.45 | $121.13 | $121.50 | 580.75K |
| Aug 19, 2026 | $124.63 | $127.36 | $121.825 | $127.31 | 842.93K |
| Aug 18, 2026 | $119.75 | $122.14 | $118.09 | $121.38 | 640.89K |
The latest Smart Investors Daily articles mentioning KYMR.
KYMR research
Company profile and research snapshot.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 14, 2026 | B of A Securities | Buy | — |
| Sep 10, 2026 | Wolfe Research | Outperform | — |
| Aug 31, 2026 | Guggenheim | Buy | — |
| Aug 27, 2026 | Wells Fargo | Overweight | — |
| Aug 6, 2026 | Barclays | Overweight | — |
No generated briefing is available yet.
SeekingAlpha · Sep 10, 2026
Kymera Therapeutics, Inc. (KYMR) Citigroup's Biopharma Back to School Summit 2026 September 10, 2026 11:20 AM EDTCompany ParticipantsNello Mainolfi -...
Benzinga · Sep 10, 2026
Wolfe Research analyst Andy Chen upgrades Kymera Therapeutics (NASDAQ:KYMR) from Peer Perform to Outperform.
Yahoo · Sep 4, 2026
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo · Sep 2, 2026
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events: Wells Fargo 21st Annual Healthcare Conference in Boston, MA on September 9 at 8:00 AM ET;Citi 2026 Biopharma Back to School Summit in New Yor
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KYMR.
